Cargando…
Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design
BACKGROUND: 20(S)-Protopanaxadiol (PPD) has a higher anti-wrinkle effect than the other glycone forms of ginsenosides. However, as PPD has low solubility in water and a high molecular weight, it cannot easily penetrate the stratum corneum layer, which is the rate-limiting step of topical skin delive...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818673/ https://www.ncbi.nlm.nih.gov/pubmed/31749618 http://dx.doi.org/10.2147/IJN.S215835 |
_version_ | 1783463635567247360 |
---|---|
author | Kim, Min-Hwan Kim, Ki-Taek Sohn, Seo-Yeon Lee, Jae-Young Lee, Chang Hyung Yang, Hee Lee, Bo Kyung Lee, Ki Won Kim, Dae-Duk |
author_facet | Kim, Min-Hwan Kim, Ki-Taek Sohn, Seo-Yeon Lee, Jae-Young Lee, Chang Hyung Yang, Hee Lee, Bo Kyung Lee, Ki Won Kim, Dae-Duk |
author_sort | Kim, Min-Hwan |
collection | PubMed |
description | BACKGROUND: 20(S)-Protopanaxadiol (PPD) has a higher anti-wrinkle effect than the other glycone forms of ginsenosides. However, as PPD has low solubility in water and a high molecular weight, it cannot easily penetrate the stratum corneum layer, which is the rate-limiting step of topical skin delivery. Thus, the objective was to enhance the topical skin deposition of PPD using an optimized nanostructured lipid carriers (NLC) formulation. NLC formulations were optimized using a Box-Behnken design. MATERIALS AND METHODS: NLC formulations were optimized using a Box-Behnken design, where the amount of PDD (X(1)), volume of the liquid lipid (X(2)), and amount of surfactant (X(3)) were set as the independent variables, while the particle size (Y(1)), polydispersity index (PDI) (Y(2)), and entrapment efficiency (EE) (Y(3)) were dependent factors. An in vitro deposition study was performed using Strat-M(®) and human cadaver skin, while in vivo skin irritation effect of the NLC formulation was evaluated in humans. RESULTS: An NLC was successfully prepared based on the optimized formulation determined using the Box-Behnken design. The particle size, PDI, and EE of the NLC showed less than 5% difference from the predicted values. The in vitro deposition of PPD after the application of the NLC formulation on a Strat-M(®) artificial membrane and human cadaver skin was significantly higher than that of the controls. Moreover, NLC formulations with and without PDD were not skin irritants in a human study. CONCLUSION: An NLC formulation for the topical delivery of PPD was successfully optimized using the Box-Behnken design, and could be further developed to enhance the topical skin deposition of PPD. |
format | Online Article Text |
id | pubmed-6818673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68186732019-11-20 Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design Kim, Min-Hwan Kim, Ki-Taek Sohn, Seo-Yeon Lee, Jae-Young Lee, Chang Hyung Yang, Hee Lee, Bo Kyung Lee, Ki Won Kim, Dae-Duk Int J Nanomedicine Original Research BACKGROUND: 20(S)-Protopanaxadiol (PPD) has a higher anti-wrinkle effect than the other glycone forms of ginsenosides. However, as PPD has low solubility in water and a high molecular weight, it cannot easily penetrate the stratum corneum layer, which is the rate-limiting step of topical skin delivery. Thus, the objective was to enhance the topical skin deposition of PPD using an optimized nanostructured lipid carriers (NLC) formulation. NLC formulations were optimized using a Box-Behnken design. MATERIALS AND METHODS: NLC formulations were optimized using a Box-Behnken design, where the amount of PDD (X(1)), volume of the liquid lipid (X(2)), and amount of surfactant (X(3)) were set as the independent variables, while the particle size (Y(1)), polydispersity index (PDI) (Y(2)), and entrapment efficiency (EE) (Y(3)) were dependent factors. An in vitro deposition study was performed using Strat-M(®) and human cadaver skin, while in vivo skin irritation effect of the NLC formulation was evaluated in humans. RESULTS: An NLC was successfully prepared based on the optimized formulation determined using the Box-Behnken design. The particle size, PDI, and EE of the NLC showed less than 5% difference from the predicted values. The in vitro deposition of PPD after the application of the NLC formulation on a Strat-M(®) artificial membrane and human cadaver skin was significantly higher than that of the controls. Moreover, NLC formulations with and without PDD were not skin irritants in a human study. CONCLUSION: An NLC formulation for the topical delivery of PPD was successfully optimized using the Box-Behnken design, and could be further developed to enhance the topical skin deposition of PPD. Dove 2019-10-25 /pmc/articles/PMC6818673/ /pubmed/31749618 http://dx.doi.org/10.2147/IJN.S215835 Text en © 2019 Kim et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kim, Min-Hwan Kim, Ki-Taek Sohn, Seo-Yeon Lee, Jae-Young Lee, Chang Hyung Yang, Hee Lee, Bo Kyung Lee, Ki Won Kim, Dae-Duk Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title | Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title_full | Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title_fullStr | Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title_full_unstemmed | Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title_short | Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design |
title_sort | formulation and evaluation of nanostructured lipid carriers (nlcs) of 20(s)-protopanaxadiol (ppd) by box-behnken design |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818673/ https://www.ncbi.nlm.nih.gov/pubmed/31749618 http://dx.doi.org/10.2147/IJN.S215835 |
work_keys_str_mv | AT kimminhwan formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT kimkitaek formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT sohnseoyeon formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT leejaeyoung formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT leechanghyung formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT yanghee formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT leebokyung formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT leekiwon formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign AT kimdaeduk formulationandevaluationofnanostructuredlipidcarriersnlcsof20sprotopanaxadiolppdbyboxbehnkendesign |